Home NDC 0002-2980-60 RETEVMO
Product NDC 0002-2980
Requested package NDC 0002-2980-60
11-digit product format 000022980
Labeler code 0002
Product ID 0002-2980_7481a510-805c-4f99-b6ae-7b44e70f5f55
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name selpercatinib
Dosage form CAPSULE
Route ORAL
Labeler Eli Lilly and Company
Application NDA213246
Marketing category NDA
Marketing start 2020-05-08
Substance SELPERCATINIB
Active strength 80 mg/1
Pharmacologic classes Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213246-001 RETEVMO SELPERCATINIB 40MG CAPSULE / ORAL RLD 2020-05-08 N213246-002 RETEVMO SELPERCATINIB 80MG CAPSULE / ORAL RLD, RS 2020-05-08
Orange Book patents# Current patent rows page 1 of 1 · 54 matching rows.
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 44 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 3 · 82 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 c2088c7a36db…2026-09-14 22:38:34 2026-08 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 84e616aacf4f…2026-08-18 06:07:40 2026-07 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 5d02ea3f76ae…
Observed Orange Book patent history# Patent history page 1 of 53 · 2,110 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N213246-001 10112942 2037-10-10 Drug substance, Drug product 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124 2037-10-10 U-3450 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124 2037-10-10 U-3949 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124 2037-10-10 U-3950 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124 2037-10-10 U-3951 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851 2037-10-10 U-3450 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851 2037-10-10 U-3949 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851 2037-10-10 U-3950 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851 2037-10-10 U-3951 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10112942*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124 2038-10-10 U-3450 Drug substance 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124 2038-10-10 U-3949 Drug substance 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124 2038-10-10 U-3950 Drug substance 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124 2038-10-10 U-3951 Drug substance 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489 2038-10-10 U-3450 Drug product 2020-10-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489 2038-10-10 U-3949 Drug product 2020-10-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489 2038-10-10 U-3951 Drug product 2020-10-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489 2038-10-10 U-3950 Drug product 2020-10-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250 2038-10-10 U-3949 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250 2038-10-10 U-3951 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250 2038-10-10 U-3950 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250 2038-10-10 U-3450 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124*PED 2039-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489*PED 2039-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250*PED 2039-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10112942 2037-10-10 Drug substance, Drug product 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124 2037-10-10 U-3450 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124 2037-10-10 U-3949 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124 2037-10-10 U-3951 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124 2037-10-10 U-3950 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851 2037-10-10 U-3951 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851 2037-10-10 U-3949 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851 2037-10-10 U-3950 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851 2037-10-10 U-3450 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10112942*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10584124 2038-10-10 U-3450 Drug substance 2020-06-05 d4dbc9d85df4…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 19 · 752 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base RETEVMO
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength SELPERCATINIB 80 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination CEGM9YBNGD Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 12 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2370164 Internal RxNorm lookup 2370170 Internal RxNorm lookup 2370172 Internal RxNorm lookup 2370174 Internal RxNorm lookup 2679805 Internal RxNorm lookup 2679808 Internal RxNorm lookup 2679810 Internal RxNorm lookup 2679812 Internal RxNorm lookup 2679813 Internal RxNorm lookup 2679814 Internal RxNorm lookup 2679815 Internal RxNorm lookup 2679816 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 0002-2980-26 RETEVMO 120 in 1 BOTTLE CAPSULE 120 22 0002-2980-60 RETEVMO 60 in 1 BOTTLE CAPSULE 60 22
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 0002-2980 RETEVMO (SELPERCATINIB) CAPSULE RETEVMO (SELPERCATINIB) TABLET, COATED [ELI LILLY AND COMPANY] 18 Current NDC, Legacy NDC, 2 package rows 20250103_7fa848ba-a59c-4144-9f52-64d090f4d828.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 0002-2980-60 00002298060 60 CAPSULE in 1 BOTTLE (0002-2980-60) 60 capsule 2020-05-08 0000-00-00 No No Current